Back to top
more

Cytokinetics (CYTK)

(Delayed Data from NSDQ)

$52.63 USD

52.63
859,208

-0.05 (-0.09%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $52.33 -0.30 (-0.57%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y

ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.

    Agios Pharma (AGIO) Q4 Loss Narrower than Expected; Stock Up

    Agios Pharmaceuticals, Inc. (AGIO) posted fourth-quarter 2016 loss of $1.34 per share, narrower than the Zacks Consensus Estimate of a loss of $1.55 but wider than the year-ago loss of $1.08.

      Kura Oncology (KURA) Catches Eye: Stock Jumps 6.8%

      Kura Oncology (KURA) saw its shares rise almost 7% in the last trading session.

        Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4

        Acorda Therapeutics, Inc. (ACOR) reported loss of 7 cents per share in the fourth quarter of 2016 (including the impact of stock-based compensation expenses), narrower than the Zacks Consensus Estimate of a loss of 18 cents.

          Zacks.com featured highlights: Milacron Holdings, Rice Midstream Partners, Calavo Growers, Cytokinetics and II-VI

          Zacks.com featured highlights: Milacron Holdings, Rice Midstream Partners, Calavo Growers, Cytokinetics and II-VI

            Falling Earnings Estimates Signal Weakness Ahead for Gilead Sciences (GILD)

            Gilead Sciences (GILD) is one stock you should avoid as it has seen a significant price decline and negative earnings estimate revisions.

              5 Profitability Stocks to Make the Most of Trump Bump

              Net income ratio selects the best profitable company on the back of Trump-led rally.

                3 Reasons Why Cytokinetics (CYTK) is a Great Momentum Stock

                Cytokinetics (CYTK) may prove to be a fresh pick that has potential to move in the right direction and is seeing momentum.

                  Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife

                  Zacks.com featured highlights: Calavo Growers, Cytokinetics, Sucampo Pharmaceuticals, State National and CryoLife

                    Cytokinetics (CYTK): An Off-the-Radar Potential Winner

                    Solid estimate revisions and an impressive Zacks Rank suggest that better days may be ahead for Cytokinetics (CYTK) and that now might be an interesting buying opportunity.

                      5 Profitable Stocks to Buy for Great Returns

                      Net income ratio gives us the exact profit level of a company and reflects the percentage of net income to total sales revenue.

                        Tirthankar Chakraborty headshot

                        New Strong Buy Stocks for December 28th

                        Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday

                          3 Biotech Stocks to Turn the Tide This Earnings Season

                          The biotech sector has strong fundamentals, and healthy product pipelines.

                            4 Biotech Stocks Looking Good this Earnings Season

                            the market sentiment seems to be improving driven by upgraded guidance, product approvals and encouraging pipeline updates.

                              David Bartosiak headshot

                              5 Stocks Rocketing to New Highs

                              These 5 stocks are breaking out to new highs on good volume